Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)

Area of Science:

• Oncology
• Pharmacology
• Epigenetics

Background:

• Peripheral T-cell lymphomas (PTCLs) are aggressive cancers with poor prognoses.
• Current first-line chemotherapy for PTCLs has limited effectiveness.

Purpose of the Study:

• To review the efficacy and safety of novel targeted agents, specifically histone deacetylase inhibitors (HDACis), in treating PTCLs.
• To explore future directions for PTCL therapy, including novel HDACis and combination treatments.

Main Methods:

• Review of clinical efficacy and safety data for approved HDACis (romidepsin, belinostat, chidamide) in PTCLs.
• Discussion of ongoing preclinical and clinical trials for novel HDACis and combination therapies.
• Exploration of mutation analysis and next-generation sequencing for understanding epigenetic alterations and targeted therapy correlations.

Main Results:

• Several HDACis (romidepsin, belinostat, chidamide) have demonstrated favorable clinical efficacy and safety in PTCL patients.
• Ongoing trials are investigating new HDACis and combination therapies for improved therapeutic outcomes.
• Mutation analysis may enhance the understanding of epigenetic profiles and guide targeted therapy selection.

Conclusions:

• HDACis represent a promising therapeutic strategy for PTCLs, offering improved outcomes compared to conventional chemotherapy.
• Multitargeted HDACis and HDACi-based prodrugs present promising avenues for future drug design and PTCL treatment.
• Further research integrating epigenetic insights with targeted therapies is crucial for advancing PTCL management.